Leap Therapeutics (NASDAQ:LPTX – Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.08) EPS for the quarter, FiscalAI reports.
Leap Therapeutics Stock Performance
Shares of Leap Therapeutics stock traded up $1.61 during trading hours on Thursday, reaching $2.05. The stock had a trading volume of 760,562,526 shares. The firm has a market capitalization of $84.95 million, a P/E ratio of -1.68 and a beta of -0.06.
Analyst Ratings Changes
Separately, Weiss Ratings started coverage on Leap Therapeutics in a report on Wednesday. They set a “sell (e+)” rating on the stock. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.
Leap Therapeutics Company Profile
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers.
Featured Articles
- Five stocks we like better than Leap Therapeutics
- How to Plot Fibonacci Price Inflection Levels
- AMD to $300 Looks Easy—Here’s Why $500 Could Be Next
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- $5B+ in Buybacks: What DraftKings, AppLovin, and Altria Are Telling You
- How Investors Can Find the Best Cheap Dividend Stocks
- 4 High-Yield Real Estate Stocks to Buy as Investors Get Defensive
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
